Events

Australia’s nuclear medicine sector is urging the Commonwealth to establish a dedicated national funding stream for radiopharmaceutical cancer therapies.

Ovarian cancer remains notoriously difficult to diagnose at an early stage, with symptoms that are often vague, non-specific and easily mistaken for less serious conditions.

Trajan Group (ASX:TRJ) has reaffirmed its full-year financial year 2026 guidance after a subdued start to the year gave way to a stronger second quarter, positioning the global analytical science and device group for improved performance in the second half.

Arovella Therapeutics (ASX:ALA) has entered a pivotal new phase of development after securing US Food and Drug Administration acceptance of its Investigational New Drug application for ALA-101.

Neuren Pharmaceuticals said FDA feedback has clarified the regulatory path for NNZ-2591 in HIE and Pitt Hopkins syndrome, supporting continued US development while European uncertainty persists following a negative EMA trend vote on its licensed Rett syndrome therapy, trofinetide.

Australia’s advanced therapies sector is set to gain new momentum with the formal establishment of a joint Advanced Therapies Advisory Group by AusBiotech and Medicines Australia, bringing together senior leaders from biotechnology, pharmaceuticals, healthcare, research, and manufacturing to help shape the future of cell and gene therapies nationwide.

As antimicrobial resistance (AMR) becomes one of the most serious threats to global health and economic stability, Australian biotechnology company Lixa has taken a decisive step to confront this challenge.

Imagion Biosystems (ASX:IBX) has announced that it has lodged an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for its MagSense targeted imaging agent.

Genetic Signatures has appointed experienced life sciences executive Maria Halasz as its new Chief Executive Officer, marking a leadership transition as the molecular diagnostics company moves into its next phase of international growth.

Argenica Managing Director Dr Liz Dallimore described the decision as a key milestone in the company’s global regulatory strategy, noting that it provides clarity and certainty as ARG-007 progresses through development.

Commenting on the announcement, Recce Pharmaceuticals’ Chief Executive Officer, James Graham, said the company was proud to deepen its engagement with the U.S. Army.

Cyclopharm (ASX:CYC) has capped off 2025 with record operating revenue, marking a pivotal year in the company’s transformation as the United States rapidly becomes its most important market.